Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		128 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Revenues
OTC product revenue					$ 25,648
Medical device revenue					14,109
Total revenues					39,757
Cost of sales					15,216
Gross profit					24,541
Operating expenses
Research and development	1,129,921	3,442,344	4,352,940	6,971,816	42,446,334
General and administrative	2,296,637	3,860,755	7,228,225	9,568,240	64,753,074
Amortization	167,780	167,780	503,340	503,340	6,621,717
Total operating loss	(3,594,338)	(7,470,879)	(12,084,505)	(17,043,396)	(113,796,584)
Gain on sale of fixed assets					55,075
Loss on extinguishment of debt					(825,867)
Investment income	310	529	1,325	898	653,195
Gain on change in fair value of warrant liability	1,246,917	1,027,554	1,435,898	1,059,730	5,580,181
Net interest expense					(8,098,004)
Net loss	(2,347,111)	(6,442,796)	(10,647,282)	(15,982,768)	(116,432,004)
Dividends on preferred stock	(43,884)	(59,465)	(145,709)	(193,623)	(10,800,584)
Net loss applicable to common shareholders	$ (2,390,995)	$ (6,502,261)	$ (10,792,991)	$ (16,176,391)	$ (127,232,588)
Basic and diluted loss per common share	$ (0.02)	$ (0.06)	$ (0.10)	$ (0.16)
Weighted average number of common shares outstanding - basic and diluted	113,166,988	109,100,408	112,073,836	104,277,935